Literature DB >> 9182910

In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy.

J P Pelletier1, J P Caron, C Evans, P D Robbins, H I Georgescu, D Jovanovic, J C Fernandes, J Martel-Pelletier.   

Abstract

OBJECTIVE: This study explored the therapeutic effect of interleukin-1 receptor antagonist (IL-1Ra), administered by gene transfer, on the progression of osteoarthritic (OA) lesions in an experimental dog model.
METHODS: Seventeen mature mongrel dogs were divided into 3 groups. Group 1 (n = 7) had an anterior cruciate ligament (ACL) section of the right knee through a stab wound incision. Groups 2 and 3 (n = 5 per group), had an ACL section of the right knee and partial synovectomy of the left knee. Each dog's synovium was subjected to enzymatic digestion, and the synovial fibroblasts were propagated in monolayer culture. Synovial cells from each dog were transduced in vitro using the retrovirus MFG with either the Escherichia coli beta-galactosidase (lac Z) gene (group 2) or the human IL-1Ra gene (group 3). Two days after surgery, the dogs received intraarticular injections as follows: group 1 phosphate buffered saline (PBS) (2 ml); group 2 autologous cells (60 x 10(6) cells/2 ml of PBS) transduced with the lac Z gene; group 3 autologous cells transduced with the IL-1Ra gene. Synovial fluid was aspirated at 2 weeks and 4 weeks. All dogs were euthanized at 4 weeks postsurgery. The right knees were dissected, and lesions were scored for macroscopic and microscopic changes. Synovial explants were dissected and representative specimens were used for histology or were cultured for 48 hours. The levels of IL-1Ra in synovial fluid and synovial explant conditioned medium were measured by specific enzyme-linked immunosorbent assay.
RESULTS: The level of IL-1Ra in synovial fluid of group 3 was 202.8 +/- 131.5 ng/ml (mean +/- SEM) at 2 weeks and 2.8 +/- 2.2 ng/ml at 4 weeks after surgery. Membrane explants isolated from dogs that received synovial cells transduced with the IL-1Ra gene (group 3) actively produced IL-1Ra (4.0 +/- 2.0 ng/gm of tissue wet weight). The severity of OA cartilage lesions was similar in groups 1 and 2. In contrast, group 3 dogs had a marked reduction in macroscopic lesion severity on the tibial plateaus (P < 0.01 for grade; P < 0.04 for size) and femoral condyles. Moreover, the histologic lesion severity was decreased on both plateaus (P < 0.06) and condyles.
CONCLUSION: This study showed that a local increase in IL-1Ra production in OA knee joints by intraarticular injection of transduced synovial cells can reduce the progression of experimentally induced lesions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9182910     DOI: 10.1002/art.1780400604

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  81 in total

1.  Benefits of recombinant adeno-associated virus (rAAV)-mediated insulinlike growth factor I (IGF-I) overexpression for the long-term reconstruction of human osteoarthritic cartilage by modulation of the IGF-I axis.

Authors:  Anja Weimer; Henning Madry; Jagadeesh K Venkatesan; Gertrud Schmitt; Janina Frisch; Anna Wezel; Jochen Jung; Dieter Kohn; Ernest F Terwilliger; Stephen B Trippel; Magali Cucchiarini
Journal:  Mol Med       Date:  2012-05-09       Impact factor: 6.354

Review 2.  Therapeutic targets in osteoarthritis: from today to tomorrow with new imaging technology.

Authors:  J-P Pelletier; J Martel-Pelletier
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

3.  A preliminary in vitro study into the use of IL-1Ra gene therapy for the inhibition of intervertebral disc degeneration.

Authors:  Christine L Le Maitre; Anthony J Freemont; Judith A Hoyland
Journal:  Int J Exp Pathol       Date:  2006-02       Impact factor: 1.925

4.  Inhibition of early response genes prevents changes in global joint metabolomic profiles in mouse post-traumatic osteoarthritis.

Authors:  D R Haudenschild; A K Carlson; D L Zignego; J H N Yik; J K Hilmer; R K June
Journal:  Osteoarthritis Cartilage       Date:  2018-12-18       Impact factor: 6.576

5.  Osteoarthritis: A single injection of anakinra for treating knee OA?

Authors:  Johanne Martel-Pelletier; Jean-Pierre Pelletier
Journal:  Nat Rev Rheumatol       Date:  2009-07       Impact factor: 20.543

Review 6.  Immune modulation to improve tissue engineering outcomes for cartilage repair in the osteoarthritic joint.

Authors:  Niamh Fahy; Eric Farrell; Thomas Ritter; Aideen E Ryan; J Mary Murphy
Journal:  Tissue Eng Part B Rev       Date:  2014-08-04       Impact factor: 6.389

7.  Editorial: Arthritis Gene Therapy Using Interleukin-1 Receptor Antagonist.

Authors:  Christopher Evans
Journal:  Arthritis Rheumatol       Date:  2018-11       Impact factor: 10.995

Review 8.  Meniscal and chondral loss in the anterior cruciate ligament injured knee.

Authors:  Hugh P Jones; Richard C Appleyard; Sanjeev Mahajan; George A C Murrell
Journal:  Sports Med       Date:  2003       Impact factor: 11.136

9.  Clinical responses to gene therapy in joints of two subjects with rheumatoid arthritis.

Authors:  Peter Wehling; Julio Reinecke; Axel W A Baltzer; Markus Granrath; Klaus P Schulitz; Carl Schultz; Rüdiger Krauspe; Theresa W Whiteside; Elaine Elder; Steven C Ghivizzani; Paul D Robbins; Christopher H Evans
Journal:  Hum Gene Ther       Date:  2009-02       Impact factor: 5.695

Review 10.  Interleukin-1 function and role in rheumatic disease.

Authors:  Georg Schett; Jean-Michel Dayer; Bernhard Manger
Journal:  Nat Rev Rheumatol       Date:  2015-12-10       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.